Replies to post #15894 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT—An analyst even more bullish on Freestyle Libre than I am:

Glucose monitor #Libre could become an $8 bln product for $ABT, says ISI's Vijay Kumar. We see these predictions in pharma all the time, but rare in med-tech. I love it! If Vijay's right, Libre would be Abbott's biggest product and outsell 3 of its 4 divisions. Here's the math: pic.twitter.com/RPv73E4Ktc

— Michelle Fay Cortez (@FayCortez) April 11, 2019